QUARTR

ACW: Xanamem missed the overall endpoint but showed significant zero-progression benefit in patients over 75

Nov 19, 2026, 08:57 GMT+11 · Less than 1 min read

ACW −82.22%

In the 247-patient XanaMIA trial, Xanamem missed statistical significance on the overall primary endpoint, while participants older than 75 showed significant improvement in zero progression rates. Treatment was well tolerated, and OLE data showed stabilization in the first 29 participants.

Original document: Actinogen Medical Limited [ACW] Press release — Nov. 19 2026

Disclaimer

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Australian stocks Quartr

© AI-generated summary is provided by Quartr

ACW chart ›





Analyze on Supercharts

Latest news ›

1 minute ago · TradingView

Geospace Technologies Reports FY2026 Revenue of $80.7 Million, Net Loss of $44.3 Million

1 minute ago · TradingView

Aeternum Resources names David de Lange interim CFO as Pieter Scholtz resigns

1 minute ago · TradingView

Stewards Ends Envy Share Escrow and $21 Million Redemption Obligation

1 minute ago · TradingView

CVB Financial director Raymond V. O'Brien to retire; restricted stock vesting accelerated

1 minute ago · TradingView

Inflection Point Acquisition VI Plans Nasdaq Delisting as Quantum Space Targets NYSE Listing

1 minute ago · TradingView

Amaze Holdings directors Amrapali Gan, Sandra Hawkins and Peter Deutschman resign

More news from Quartr ›

6 minutes ago · Quartr

ONCY: All director nominees and AGM proposals passed, including annual executive compensation votes

6 minutes ago · Quartr

GEOS: FY26 losses deepened, but a $100M-plus backlog anchors the FY27 recovery plan

8 minutes ago · Quartr

CERT: Production and earnings surged as growth plans advanced across Argentina, Portugal and Canada

9 minutes ago · Quartr

UGI: Operating income advanced as adjusted earnings weakened; a major LPG separation is planned

12 minutes ago · Quartr

Plato Income Maximiser: Monthly fully franked income remained central as shareholders backed director re-elections

MADE BY HUMANS

English

Select market data provided by ICE Data Services.

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved.

SEC filings and other documents provided by Quartr.

© 2026 TradingView, Inc.

MORE PRODUCTS

News Flow
Portfolios
Yield Curves
Options
Macro Maps
Pine Script®
MCP Server

APPS

Mobile
Desktop

Media kit

MERCH

Tarot cards for traders
The C63 TradeTime

POLICIES & SECURITY

Terms of Use
Disclaimer
Privacy Policy
Cookies Policy
Accessibility Statement
Security tips
Bug Bounty program
Status page

LOOK FIRST / THEN LEAP.